Trial Profile
WORTH (which one is right here?): Randomised, crossover study to identify predictive baseline characteristics of response to pioglitazone or vildagliptin as second or third line therapy in patients with Type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms WORTH
- 12 Dec 2020 Status changed from recruiting to completed.
- 24 Jul 2019 Status changed from not yet recruiting to recruiting.
- 29 Nov 2018 New trial record